Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma

Technology appraisal guidance
Reference number: TA137
Published: 27 February 2008

Appendix A: decision paper presented to the Institute's Guidance Executive

Appendix A: decision paper presented to the Institute's Guidance Executive

Appendix A: decision paper presented to the Institute's Guidance Executive
08 March 2011
(84.25 Kb 24 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 08 March 2011